M. Sulecki

Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer

S. Ramalingam, C. Belani, W. Gooding, 2010, Cancer.

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.

K. Foon, M. Boyiadzis, A. Tarhini, 2012, Blood.

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.

K. Foon, A. Raptis, M. Boyiadzis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia.

R. Shadduck, M. Sulecki, C. Rosenfeld, 1991, Experimental hematology.

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours

J. Kirkwood, S. Moschos, A. Tarhini, 2011, British Journal of Cancer.

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)

S. Ramalingam, A. Argiris, J. Schiller, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II randomized trial of carboplatin , paclitaxel , bevacizumab with or without cixutumumab ( IMCA 12 ) in patients with advanced non-squamous , non-small-cell lung cancer : a trial of the ECOG-ACRIN Cancer Research Group ( E 3508 )

S. Ramalingam, A. Argiris, J. Schiller, 2017 .

Use of granulocyte-macrophage colony-stimulating factor in patients with malignancy and bone marrow failure.

R. Shadduck, C. Rosenfeld, R. Stoller, 1990, International journal of cell cloning.

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study

S. Ramalingam, Martin R. Weber, C. Belani, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment of ganciclovir-induced neutropenia with recombinant human GM-CSF.

R. Shadduck, C. Rosenfeld, D. Przepiorka, 1991, The American journal of medicine.

Phase I trial of lomeguatrib (PN) combined with dacarbazine (DTIC) for treatment of patients with melanoma and other solid tumors: Initial results.

J. Kirkwood, H. Tawbi, S. Moschos, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.